src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-8050569412065003" crossorigin="anonymous">[/script]

Roche, Zealand Pharma strike $5.3 billion deal for obesity drug newsthirst.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma’s obesity drug candidate, as the two firms seek to compete in the burgeoning weight loss drug market. The deal will see the two companies co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as…

Read More